Consistent with advances in HIV/AIDS treatment regimens that now combine antiretrovirals from different classes, experts anticipate that microbicides based on a combination of ARVs may maximize their protective effect:
- Combination microbicides could target HIV at different points in the life cycle.
- Multiple ARVs may reduce the chance of acquiring drug-resistant HIV over time.
Where HIV may be resistant to one drug, another drug with a different mechanism of action delivered in the same product may be effective.
The use of newer ARV combination treatments has proven to strongly diminish the residual replication of HIV and is therefore much more effective in preventing the development of HIV drug resistance. Scientists anticipate the same may hold true for ARV combination prevention methods such as microbicides.
Combination Products in IPM’s Pipeline
The most advanced combination microbicide in IPM’s portfolio contains the NNRTI dapivirine (TMC120) and the CCR5 blocker maraviroc in a long-acting vaginal ring that would release the two drugs slowly over the course of a month. Researchers from IPM and IPM's clinical trial partner the Microbicide Trials Network (MTN) conducted a Phase I trial to evaluate the safety of the dapivirine-maraviroc ring, the first trial of its kind. IPM is now optimizing the ring following the completion of the trial.
IPM is also exploring the development of vaginal rings that combine dapivirine and DS003, a potent new gp120 inhibitor, and dapivirine and darunavir, a protease inhibitor currently used for HIV treatment.
Learn more about how ARV-based microbicides work.